Chinese company unveils new tech that could revolutionize electric vehicles: 'Truly amazing'
New electric vehicle battery technology that could put an end to range anxiety has been unveiled at the 2025 Shenzhen International Battery Fair in China.
Among Chinese battery manufacturer SEVB's announcements was its Star Chaser 2.0 battery system that delivers over 93 miles of range from just one minute of charging, according to a report by Interesting Engineering.
Electric vehicles are a major component in shifting the world away from dirty fuels and adopting clean energy alternatives. These machines don't produce any tailpipe emissions and can run on electricity generated by sustainable sources.
Unfortunately, charging an EV takes significantly longer than filling a tank with gasoline. DC fast chargers, which are some of the fastest, still take between 20 minutes and an hour to get a battery up to 80%.
Battery charging speeds are graded with a "C" rating. SEVB's original Star Chaser, which was launched in 2022, was groundbreaking at the time with 4C charging rates.
The company's new Star Chaser 2.0 uses a combination of liquid cooling, flexible printed circuits, and added safety features to achieve the incredible feat of charging at 12C, the report explained.
The Xinxingchi 2.0 Kiloamp Extreme Charging Edition is essential to the technology, allowing the battery to be charged with a record 1400 A current when paired with a vehicle that has a 1,000-volt system.
The resulting 1.4 megawatt flash-charging succeeds in making EV charging as fast as refueling a traditional vehicle, which could tilt the scales in favor of EVs for consumers who have been on the fence about upgrading.
The company also announced the Xinxingchi 2.0 Long Range Edition, which charges at 6C but offers over 500 miles of range.
Being able to charge quickly can make electric vehicles far more appealing, but there are already inherent benefits to the technology that make them better than more typical cars powered by internal combustion engines.
Would you buy an EV if it only took 5 minutes to charge?
Sign me up
No way
Depends on the cost
Depends how much range it has
Click your choice to see results and speak your mind.
EVs are extremely energy efficient, converting up to 91% of the energy from the battery and regenerative braking system into forward motion. Gasoline-powered vehicles only get about 25% energy efficiency from burning dirty fuels.
That efficiency also means that the annual costs to fuel an electric car will be significantly lower. A 2018 study from the University of Michigan found that EVs cost around $485 to fuel every year, compared to $1,117 in annual fuel costs for a gasoline vehicle.
Plus, homes with a solar panel system and battery storage allow EV owners to charge their vehicles with clean energy and reduce those costs even further. EnergySage offers expert advice and quote comparisons to help consumers who are interested in upgrading.
Interesting Engineering added that SEVB is also trying to keep their products at a competitive price, so that the three-year cost of EV ownership will be lower than that of a gasoline-powered car.
Commenters on the Interesting Engineering report seemed hopeful for the future of this technology.
"Sounds like truly amazing technology," one person said. "Let's hope this battery can be manufactured at scale."
Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
-- Potential First-in-Class Respiratory Combination Vaccine Candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) Enter the Clinical Trial Stage -- SHANGHAI, June 17, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced that enrollment of the first participants has been completed in a Phase I clinical trial evaluating SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) respiratory combination vaccine candidates based on prefusion-stabilized F (PreF)-Trimer subunit vaccine antigens utilizing Clover's Trimer-Tag vaccine technology platform. "We are pleased to announce the Phase I clinical trial initiation of our potential first-in-class combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), further demonstrating the differentiated value of our validated Trimer-Tag platform," said Joshua Liang, Chief Executive Officer & Board Director of Clover. "While currently approved protein-based RSV vaccines are safe & effective, critical gaps persist globally, including the inability to prevent significant respiratory disease burden caused by other viruses related to RSV such as human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3). Thus, we look forward to the clinical trial results for our respiratory combination vaccine candidates in order to maximize our impact on public health globally." In October 2024, Clover announced Phase I results in 70 older adults (60-85 years) for Clover's non-adjuvanted RSV PreF vaccine candidate (SCB-1019) compared head-to-head to GSK's AS01E-adjuvanted RSV vaccine (AREXVY), and results indicated a potential best-in-class combined immunogenicity & tolerability profile of SCB-1019. These results supported the further development and evaluation of SCB-1019 in combination with the PreF-Trimer antigens for hMPV and PIV3, which are also utilizing the Trimer-Tag platform. The ongoing Phase I trial for Clover's combination vaccine candidates is enrolling up to 192 older adults (60-85 years), and the participants will be randomized to receive either SCB-1022 (RSV+hMPV), SCB-1033 (RSV+hMPV+PIV3) or SCB-1019 (RSV) comparator. The study will assess safety, reactogenicity and immunogenicity. About Clover Clover Biopharmaceuticals is a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing and commercial capabilities as well as strong partnerships with organizations globally, Clover has a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable. Clover Forward-looking Statements This press release contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words "aim," "anticipate," "believe," "could," "estimate," "expect," "going forward," "intend," "may," "might," "ought to," "plan," "potential," "predict," "project," "seek," "should," "will," "would" and the negative of these words and other similar expressions, as they relate to us or our management, are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. We give no assurance that these expectations and assumptions will prove to have been correct. Because forward-looking statements relate to the future, they are participant to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. We caution you therefore against placing undue reliance on any of these forward-looking statements. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time. View original content: SOURCE Clover Biopharma Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Undiscovered Gems in Asia to Explore This June 2025
As geopolitical tensions in the Middle East and trade-related concerns weigh on global markets, Asian stocks present a unique landscape of opportunities. With small-cap indices experiencing volatility, discerning investors may find potential in lesser-known companies that demonstrate resilience and innovation amidst changing economic conditions. Name Debt To Equity Revenue Growth Earnings Growth Health Rating Toho 72.03% 6.01% 64.19% ★★★★★★ Yashima Denki 2.40% 0.14% 21.00% ★★★★★★ FALCO HOLDINGS 4.93% -0.16% 1.44% ★★★★★★ Hefei Gocom Information TechnologyLtd NA 9.11% -12.23% ★★★★★★ Center International GroupLtd 18.20% 0.69% -31.63% ★★★★★★ ISE Chemicals 1.40% 15.34% 32.61% ★★★★★★ Shanghai SK Automation TechnologyLtd 37.27% 33.22% 12.18% ★★★★★☆ Guangdong Transtek Medical Electronics 18.14% -7.58% -3.26% ★★★★★☆ Daoming Optics&ChemicalLtd 33.83% 1.38% 5.82% ★★★★★☆ ITCENGLOBAL 66.11% 16.65% 1.99% ★★★★★☆ Click here to see the full list of 2614 stocks from our Asian Undiscovered Gems With Strong Fundamentals screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Value Rating: ★★★★★★ Overview: Snt Dynamics Ltd. engages in the manufacturing and sale of precision machinery, with a market capitalization of ₩1.25 trillion. Operations: Snt Dynamics Ltd. generates revenue primarily from its Machinery Business and Transportation Equipment Business, with the latter contributing significantly more at ₩672.52 billion compared to the former's ₩2.88 billion. Snt Dynamics Ltd. stands out in the aerospace and defense sector with a robust 96% earnings growth over the past year, surpassing industry averages. Despite its small size, this debt-free company boasts a favorable price-to-earnings ratio of 12.4x, slightly undercutting the KR market's 12.6x benchmark. Recent financials reveal net income at KRW 17,769 million for Q1 2025, up from KRW 12,880 million last year. The firm announced a private placement to issue bonds worth KRW 110 billion which are fully exchangeable into shares starting July 2025; such strategic moves may bolster future growth prospects significantly. Get an in-depth perspective on Snt DynamicsLtd's performance by reading our health report here. Evaluate Snt DynamicsLtd's historical performance by accessing our past performance report. Simply Wall St Value Rating: ★★★★★☆ Overview: Daou Technology Inc., along with its subsidiaries, offers IT and finance services and has a market capitalization of approximately ₩1.42 trillion. Operations: Daou Technology Inc. generates revenue primarily from its finance segment, with significant contributions from the Finance - Wholesale General Manager (₩8.22 billion) and Finance - Retail General Manager (₩2.52 billion) divisions. The non-financial segment includes System Construction, which adds ₩452.49 million to the revenue stream. Daou Technology, a noteworthy player in the tech sector, has shown impressive financial strides. With earnings growth of 76.1% over the past year, it outpaced its industry peers significantly. The company reported sales of KRW 21.28 billion for Q1 2025, up from KRW 12.50 billion last year, though net income slightly dipped to KRW 102.11 million from KRW 103.12 million previously. Despite not being free cash flow positive, Daou's interest payments are well-covered by EBIT at a robust rate of 97 times coverage and its debt-to-equity ratio improved from over five years to stand at a healthier level today. Dive into the specifics of Daou Technology here with our thorough health report. Assess Daou Technology's past performance with our detailed historical performance reports. Simply Wall St Value Rating: ★★★★☆☆ Overview: Gallant Micro. Machining Co., Ltd. specializes in the production and sale of machinery, equipment, precision molds, and various components across Taiwan, China, and international markets with a market cap of NT$16.65 billion. Operations: Gallant Micro. Machining Co., Ltd. generates revenue primarily from its machinery and equipment segment, with NT$1.81 billion attributed to this area, supplemented by contributions from KMC Corporation at NT$755.95 million. Gallant Micro. Machining, a small player in the semiconductor space, has shown impressive earnings growth of 40.9% over the past year, outpacing the industry's 10.8%. Despite this growth, their recent Q1 2025 results reported a drop in sales to TWD 430.22 million from TWD 695.32 million and net income to TWD 45.84 million from TWD 139.36 million year-over-year, reflecting challenges amid volatility in share prices over three months. The debt-to-equity ratio has increased significantly from 44% to 91%, though with a satisfactory net debt level at just over 13%, interest coverage remains solid and non-cash earnings are high. Click here and access our complete health analysis report to understand the dynamics of Gallant Micro. Machining. Examine Gallant Micro. Machining's past performance report to understand how it has performed in the past. Investigate our full lineup of 2614 Asian Undiscovered Gems With Strong Fundamentals right here. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSE:A003570 KOSE:A023590 and TPEX:6640. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Washington Post
41 minutes ago
- Washington Post
Oil prices rise and US futures fall as Israel urges residents of Iran's capital to evacuate
BANGKOK — Oil prices resumed their upward climb and U.S. futures were lower early Tuesday after Israel's military issued an evacuation warning to 330,000 people in Iran's capital Tehran. Asian shares were mixed. The evacuation warning was for a part of Tehran, a city of 9.5 million, that houses the country's state TV and police headquarters and three large hospitals, including one owned by Iran's paramilitary Revolutionary Guard. U.S. President Donald Trump announced he was returning from the G7 summit in Canada a day early due to the intensifying conflict. The futures for the S&P 500 and the Dow Jones Industrial Average were down 0.3%. In Asia, Tokyo's Nikkei 225 index climbing 0.6% to 38,547.56 as the Japanese central bank opted to keep its key interest rate unchanged at 0.5%. The Bank of Japan has been gradually raising its rate from near zero and cutting back on its purchases of Japanese government bonds and other assets to help counter inflation. It said economic growth was likely to moderate and there was some weakness in consumer sentiment, housing investment. 'In particular, it is extremely uncertain how trade and policies in each jurisdiction will evolve and how overseas activity and prices will react to them,' the BOJ's statement said. Chinese shares edged lower. In Hong Kong, the Hang Seng slipped 0.1% to 24,038.56. The Shanghai Composite index declined 0.2% to 3,382.14. In South Korea, the Kospi gained 0.4% to 2,956.88. Australia's S&P/ASX 500 gave up 0.1% to 8,543.60. Taiwan's Taiex gained 0.6% and in Bangkok the SET was little changed. As Israel and Iran attack each other the fear remains that a wider war could constrict the flow of Iran's oil to its customers. That in turn could raise gasoline prices worldwide and keep them high, though spikes in prices from previous conflicts have been brief. Crude jumped 7% late last week after Israel's attack on Iranian nuclear and military targets . Early Tuesday, U.S. benchmark crude oil gained 31 cents to $72.08 per barrel, while Brent crude, the international standard, was up 33 cents at $73.56 per barrel. On Monday, the mood was calm on Wall Street, as the S&P 500 climbed 0.9% to reclaim most of its drop from Friday . It closed at 6,033.11. The Dow Jones Industrial Average added 0.8% to 42,515.09, and the Nasdaq composite gained 1.5% to 19,701.21. U.S. Steel rose 5.1% after Trump signed an executive order on Friday paving the way for an investment in the company by Japan's Nippon Steel. Trump would have unique influence over the operations of U.S. Steel under the terms of the deal. They helped offset drops for defense contractors, which gave back some of their jumps from Friday. Lockheed Martin fell 4%, and Northrop Grumman sank 3.7%. The price of gold receded after jumping on Friday, when investors were looking for someplace safe to park their cash . An ounce of gold fell $14.60 to $3,402.40 per ounce. Investors have other concerns, key among them Donald Trump's tariffs , which still threaten to slow the U.S. economy and raise inflation if Washington doesn't win trade deals with other countries. The specter of tariffs was looming over the meeting of the Group of Seven meeting of major economies in Canada. Later this week, the Federal Reserve is set to discuss whether to lower or raise interest rates, with the decision due on Wednesday. The nearly unanimous expectation among traders and economists is that the Fed will stand pat. The Federal Reserve has hesitated to lower interest rates after one cut late last year. It is waiting to see how much Trump's tariffs will hurt the economy and raise inflation , which has remained tame recently, and is near the Fed's 2% target. More important for financial markets on Wednesday will likely be forecasts for where Fed officials they see the economy and interest rates heading in upcoming years. In other dealings early Tuesday, the U.S. dollar fell to 144.59 Japanese yen from 144.75 yen. The euro rose to $1.1564 from $1.1562. ___ AP Business Writer Stan Choe contributed.
